Introduction
Duchenne muscular dystrophy (DMD) is a severe Xlinked disorder caused by mutations in the dystrophin gene. Lack of dystrophin in patients' muscle causes instability of the sarcolemma resulting in fiber necrosis, progressive wasting of muscle and replacement by fibrotic and adipose tissue. Since DMD is a relatively common disease with a devastating course for which there is no effective treatment, it is a major target for gene therapy. One aim of gene therapy is to introduce dystrophin cDNA into a sufficient number of muscle fibers to prevent repeated cycles of necrosis before failure of regeneration sets in. Dystrophin is probably a neoantigen in DMD patients and animal models, and may therefore be able to induce immunoreaction. 1 However, tolerance to the neoantigen may be evoked by revertant fibers; indeed, naked cDNAs encoding fulllength or truncated mouse dystrophin seem not to evoke either a humoral or cytotoxic immune response in mdx mice. 2 Another possible therapeutic approach is to upregulate utrophin, a protein not foreign to DMD patients, and one highly homologous to dystrophin both functionally and structurally. 3, 4 Utrophin is normally present at the neuromuscular junction of mature muscle fibers, and is also expressed throughout the sarcolemma of fetal and regenerating fibers. [5] [6] [7] Utrophin is also expressed at a low level throughout the sarcolemma in the muscle of DMD patients and animal models. 8 Ebihara et al 9 have shown that in muscles of mature mdx mice injected with an adenovirus encoding a utrophin minigene, there was significantly greater persistence of transgene expression and lower inflammation compared to muscles injected with a dystrophin minigene. Furthermore, transgenic mdx mice expressing high levels of exogenous utrophin show a marked reduction in dystrophic pathology and increased expression of dystrophin-associated proteins (DAPs) at the sarcolemma. 10, 11 DAP expression is greatly reduced in DMD patients' muscles. 12 It is hypothesized that, together with dystrophin, DAPs constitute a link between the extracellular matrix and the subsarcolemmal cytoskeleton that stabilizes the muscle membrane. 13, 14 Reconstitution of this link through mini-utrophin gene transfer should improve the clinical phenotype and histopathology of skeletal muscle in dystrophic subjects.
Other animal models genetically homologous to DMD include hypertrophic feline muscular dystrophy (HFMD) 15 and canine X-linked muscular dystrophy (CXMD). 16 However, the young mdx mouse and HFMD cat, unlike DMD children, exhibit mild clinical features and little or no endomysial fibrosis. 17, 18 By contrast, newborn CXMD dogs have a severe progressive course and clinical signs similar to DMD. 19 In DMD and CXMD, skeletal muscle shows early fiber necrosis and regeneration, associated with perimysial and endomysial connective tissue proliferation. 20, 21 CXMD is therefore a highly suitable animal model for DMD, particularly with regard to potential therapeutic approaches. Correction of the consequences of dystrophin deficiency by gene transfer in the canine model should help us to develop a similar treatment strategy in DMD.
In the present study, we injected tibialis anterior (TA) muscles of newborn CXMD dogs with a mini-utrophin adenoviral vector (AdV-Utr). We examined utrophin expression by RNA and protein analysis at 10, 30 and 60 days postinjection in cyclosporin-treated and -untreated animals. We also evaluated the extent of fibrosis and expression of DAPs as measures of the functional efficacy of mini-utrophin transfer.
Results

Evaluation of mini-utrophin expression
Evidence of the presence of transgenic utrophin transcript was obtained by RNA analysis.. Injected muscles of animals killed at 10, 30 and 60 days were processed for RT-PCR, and a band of the expected 136 bp was detected in both cyclosporin-treated and -untreated animals. The band was absent from TA muscles of uninjected dystrophic dogs (Figure 1a) . The base sequence of the band was identical to that of the minigene. This exogenous transcript was also detected in heart and diaphragm, suggesting adenovirus diffusion through the circulation (Figure 1b) .
In situ hybridization in injected muscles from cyclosporin-treated animals produced, in areas corresponding to high expression of transgenic utrophin, an evident signal on cell surfaces and cytoplasm (data not shown). Use of the sense probe resulted in lack of staining, confirming the probe specificity. In situ hybridization in uninjected muscles also showed no specific signal.
The presence of the shortened utrophin in the injected TA muscles at 60 days postinjection was confirmed by immunoblot. Recombinant utrophin was distinguished from the endogenous form by its smaller molecular weight: 200 versus 427 kDa ( Figure 2 , lane 1), and was absent from uninjected dystrophic and normal muscles ( Figure 2, lanes 2 and 3) .
The expression of transgenic utrophin was clearly identified by the presence of conspicuous utrophin Figure 1 RT-PCR of total RNA from CXMD skeletal muscle. Total RNA was extracted from 30 mg of frozen muscle and RT-PCR was performed using specific primers for mini-utrophin. (a) Agarose gel shows RT-PCR product from TA muscles of cyclosporin-treated dystrophic dogs at 10, 30 and 60 days after AdV-Utr injection, and from a control dystrophic TA muscle; (b) RT-PCR product from heart and diaphragm of an injected animal, a positive control (injected TA muscle), and no-Reverse Transcriptase negative controls. A band of the expected 136 bp is present in TA muscle, heart and diaphragm of the injected animals. Figure 2 Immunoblot detection of utrophin after AdV-mediated gene transfer. Muscles of 60-day-old CXMD dogs injected with AdV-Utr, CXMD-uninjected and normal dogs were lysed, and processed for immunoblot analysis using monoclonal antibodies specific for the Nterminus of utrophin. The recombinant utrophin is present only in the AdV-Utr-injected muscle. The endogenous utrophin has a higher molecular weight. Numbers on the left indicate positions of calibration standards (kDa).
Utrophin gene transfer in CXMD M Cerletti et al immunostaining, which was much more intense than that normally present on the fiber surfaces of uninjected dystrophic muscles. Transduced fibers had a strong, sharp and complete peripheral ring of utrophin staining and conspicuous cytoplasmic positivity (Figure 3a) . Utrophin positivity in controls was weaker and patchy at the sarcolemmal rim, and absent from the cytoplasm.
In cyclosporin immunosuppressed animals at 10, 30 and 60 days after AdV-Utr injection, positive fibers were grouped in clusters of variable size. Strong immunoreactivity on muscle fiber surface and inside most fibers of such clusters could readily be seen (Figure 3a) . Clusters of positive fibers often extended over several fascicles, and included up to 1230 fibers. The proportion of fibers per field expressing the transgene varied from 2 to 78% in 30-day-old animals and from 2 to 91% in 60-day-old animals. The average number of such fibers, calculated over the entire muscle section, was 14.4723.3% at 30 days and 16.8728.5% at 60 days (high standard deviations are because of great variability between animals and fields). In the single AdV-Utr-injected muscle from the animal killed at 10 days, 18% of the fibers from the injected TA muscle were transgene positive.
In injected muscles from animals that had not been cyclosporin treated, only scattered transduced fibers were observed at 30 and 60 days ( Figure 3b ); average proportions were 1.1171.65% at 30 days and 1.6371.21% at 60 days. At 10 days, a single cluster of positive fibers was observed in the TA of the single cyclosporinuntreated animal.
Mitigation of dystrophic phenotype
We found that the signal intensities of the DAPs bdystroglycan and b-sarcoglycan were much greater at the surface of fibers expressing the recombinant utrophin than fibers not expressing this exogenous protein ( Figure  3c -f), indicating that AdV-mediated utrophin transfer A further demonstration of improved dystrophic phenotype was obtained by assessing fibrosis. This is known to be significantly increased at 60 days. 21 Fibrosis was measured in the 60-day-old dystrophic dog: the proportion of connective tissue in transgene-positive areas was 11.7571.68%, significantly (po0.0001) less than in transgene-negative areas (21.9972.74%) (see also Figure 4 ). Central nuclei are not increased in the dystrophic dog (unlike in the mdx mouse) and cannot therefore be used as a measure of transgene efficacy. 21 Detection of antiutrophin and anti-AdV antibodies, and cell-mediated immune response
We looked for antibodies against transgene and viral surface antigens in all injected dogs. Neither immunohistochemistry nor blocking test gave a positive utrophin signal, meaning that antibodies to utrophin, if present, were too low to be detected.
Antibodies against the viral capsid were detected in serum samples from nonimmunosuppressed dogs at 30 and 60 days after AdV-Utr treatment (titers 200-300), and Utrophin gene transfer in CXMD M Cerletti et al from cyclosporin-treated animals (titers 0-50). Antibodies were not detected in samples from 5-day-old dogs.
The cell-mediated immune response was measured by counting CD4-positive mononucleated cells per 100 muscle fibers in the 60-day-old animals. The average count of CD4-positive cells was one per 100 muscle fibers in the cyclosporin-treated animals, and six per 100 fibers in the cyclosporin-untreated animals.
Discussion
We have demonstrated that mini-utrophin is efficiently expressed at the extrajunctional membrane in a significant number of CXMD muscle fibers after AdV-mediated gene transfer, and that its expression is stable for at least 60 days in immunosuppressed dogs.
We used RT-PCR -involving amplification of a 136 bp region of the transgene -and sequencing to show that exogenous transcript was present. In situ hybridization revealed it was located in muscle areas corresponding to high expression of transgenic utrophin with signal evident in cytoplasm and on cell surfaces (data not shown). By RT-PCR, we also detected exogenous utrophin transcript in heart and diaphragm of cyclosporin-treated animals (other tissues were not available for testing). This is likely to be because of diffusion of adenovirus particles into the circulation.
At 60 days after injection the expression of miniutrophin was investigated by immunoblot. This protein, which was absent from uninjected muscles, could be distinguished from endogenous utrophin by its smaller molecular weight (200 versus 427 kDa). We found that the intensity of the 427 kDa band was greater than that of the transgenic utrophin. There are several possible reasons for this: the known upregulation of the endogenous sarcolemmal utrophin in dystrophic muscle; the presence of blood vessels and nerves in the specimen used for immunoblot; and the larger number of nontransduced fibers in the specimen.
Analysis of cryostat sections of TA muscle revealed a high level of expression of mini-utrophin in clusters of fibers, presumably those closest to the injection point. In many fibers, the utrophin excess produced diffuse immunostaining in the cytoplasm in addition to sarcolemmal positivity.
An important finding of our study was that the exogenous utrophin could functionally compensate for the lack of dystrophin since utrophin-transduced fibers expressed much higher levels of the DAPs b-dystroglycan and b-sarcoglycan than areas of the muscle where the transgenic utrophin was not expressed. We previously showed that endogenous utrophin is upregulated in the muscle of CXMD dogs. 22 However, the upregulation is not enough to efficiently reconstruct the link with the DAP complex: probably a greater quantity of utrophin is required for this. We also found that areas expressing transgenic utrophin had less severe histopathological features and considerably reduced fibrosis as determined both by quantitation of type III collagen 23 and by Masson's trichrome staining.
Although utrophin and dystrophin are different proteins, they share considerable structural and sequence homology. 24, 25 One difference between them is that the rod domain actin-binding site of dystrophin is not present in utrophin. 26 Nevertheless, Rybakova et al 27 showed that overexpression of utrophin in mdx muscle rescued the defective link between costameric actin filaments and the sarcolemma. They concluded that, even if molecular epitopes differ between the two proteins, utrophin and dystrophin seem to be functionally interchangeable actin-binding proteins. Our utrophin construct also proved able to locate correctly at the cell surface and increase DAPs expression. Immunoreaction against the viral vector and transgene constitutes an important limit to the efficacy of gene therapy. Thus, in the present study, transgene persistence was achieved only when associated with cyclosporin immunosuppression. We detected humoral antiadenovirus antibodies in serum samples from nonimmunosuppressed dogs and in smaller amounts from cyclosporin-treated animals. Recently developed AAV vectors have been shown to be less immunogenic than the adenoviral vector we used, [28] [29] [30] and one may presume therefore that immunological problems related to the vector will be overcome.
Some studies have reported that transgene antigenicity is a major determinant of the duration of expression in vivo. 31, 32 One reason why utrophin gene therapy has been evaluated as a possible treatment for DMD is that it may avoid the neoantigenicity of dystrophin. However, Wang et al 30 showed that mdx mouse muscles transduced with AAV vectors carrying human minidystrophin genes persistently expressed the transgenes, with no cytotoxic T lymphocyte-mediated destruction of myofibers. It is possible that revertant fibers may induce immunological tolerance to dystrophin.
Although we detected no antibodies against utrophin by two methods (direct and blocking), it is possible that the truncated synthetic utrophin construct we used elicited a weak immune response. The mini-utrophin was constructed from the N-and C-terminal regions of murine and human cDNA, respectively. These regions are highly conserved and it is likely that canine endogenous utrophin expression (present within multiple tissues) conferred a certain degree of immunologic tolerance to AdV-encoded hybrid utrophin. A further improvement of utrophin gene transfer in the CXMD dog is predictable by using canine utrophin.
To conclude, our study shows that utrophin is able to mitigate the muscular dystrophy phenotype in the injected areas of muscles of dogs with CXMD -a close animal model of DMD. The strategy is therefore highly promising as a potential therapeutic approach to DMD in humans. If more recently developed AAV vectors are used, this will further reduce the dimension of the immunogenicity problem. Further studies are required on the canine model to assess both the long-term stability of utrophin expression and the functional effect of this on the dystrophin-deficient muscle.
Materials and methods
Golden Retriever dogs
Five affected, four heterozygous female and six normal puppies from three litters were used. All animals were from a colony of CXMD dogs established from carriers obtained from Dr Barry J Cooper of Cornell University, Ithaca, NY; maintained in our facilities in accordance with European legislation. Dystrophic versus carrier phenotype was identified in the newborn puppies from high levels of serum creatine kinase (CK) and later confirmed by muscle biopsy.
Mini-utrophin adenoviral vector
The construction of an E1+E3-deleted replication-defective serotype-5 human adenovirus expressing a shortened version of utrophin is described in detail elsewhere. 33 The utrophin employed is a 6059 bp synthetic construct. 10 (Sequence 8 from Patent WO0125461; GeneBank accession number AX107972.) The N-and C-terminal regions were derived, respectively, from murine and human cDNA. The transgene expression was driven by the ubiquitous human cytomegalovirus (CMV) promoter/enhancer elements.
Intramuscular injection of AdV-Utr
A 100 ml of purified AdV-Utr (OD titer 7 Â 10 11 particles/ ml) was injected into the TA muscle of both limbs of 2-day-old pups (except in the two animals killed at 10 days in which only one TA was injected). Injections were done under isofluorane general anesthesia. The muscle is about 2-3 cm long and 5-6 mm wide at its thickest point. The animals were euthanized 10, 30, and 60 days after injection; both left and right TA muscles were removed. Heart and diaphragm muscle biopsies were also taken. All samples were immediately frozen in liquid nitrogencooled isopentane. TA muscles of six uninjected animals from previous litters, euthanized at 9 and 11 days (one each), and 30 and 60 days (two each), were used as controls. 22 Five injected animals were immunosuppressed with cyclosporin (19.5 mg/kg) from one day of age as follows: of those killed at 10 days one dystrophic animal was cyclosporin treated and one carrier was not; of those killed at 30 days, one dystrophic animal and one carrier were treated and one dystrophic animal was not; of those killed at 60 days, one dystrophic animal and one carrier were cyclosporin treated and one dystrophic animal and one carrier were untreated. Cyclosporin levels in blood were measured twice a week and dose adjustments made whenever necessary.
RNA analysis
Total RNA was isolated from 30 mg of muscle tissue using the SV Total RNA Isolation System including a DNase treatment step. (Promega Corporation, Madison, WI, USA). A measure of 2.5 mg of RNA was reverse transcribed in the presence of 1 mM of each deoxynucleoside triphosphate, 8 pmol/ml random hexamers, 1 U/ml RNase inhibitor and 10 U/ml reverse transcriptase. A negative RT sample control (no M-MLV reverse transcriptase) was done to ensure the RNA used was free of viral DNA. One pair of primers (forward 5 0 -TCCA-CAGAAGGACCTATTGG-3 0 and reverse 5 0 -TTCTCCCAATTCGGTGGTTG-3 0 ) was used to amplify a 136 bp PCR product of the mini-utrophin.
PCR reactions were performed in 50 ml containing 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH 4 ) 2 SO 4 , 2 mM MgSO 4 , 200 mM of each deoxynucleoside triphosphate, and 1.25 U of Pfu DNA polymerase, with 50 pmol of each primer described above. Amplification was carried out for 35 cycles at 951C for 30 s, 551C for 30 s, 721C for 2 min, followed by a single extension at 721C for 5 min. Approximately 200 ng of product and the original primers were used in a sequencing reaction with the Prism Ready Reaction Dyedeoxy Terminator Cycle Sequencing Kit (Perkin-Elmer Corp.), using AmpliTaq DNA polymerase according to the manufacturer's instructions and resolved on an ABI 373A DNA sequencer.
In situ hybridization
In situ hybridization to specifically detect the exogenous utrophin was performed on cryosections (6 mm) of selected TA muscles from control and injected CXMD dogs using a synthetic oligonucleotide probe. Sections were placed on 0.1% poly (L-lysine)-coated slides, postfixed for 10 min in 4% paraformaldehyde in PBS (pH 7.2), dehydrated, and stored frozen at À801C until use. Hybridization with an antisense digoxigenin-labeled oligonucleotide complementary to the utrophin minigene mRNA (5 0 -CTTCTTCGGGTTCGTCCTTGACG-GAGGAGGCAATTGTTTCCGACTCGTAAACGTTTT-3 0 ) was performed overnight at 421C in a solution containing 50% formamide, 10% dextran sulfate, 25 mM HEPES (pH 7.0), 330 mM NaCl, 100 mM DTT, 1 Â Denhardt's, 200 mg/ml denatured salmon sperm DNA, 200 mg/ml poly(dA), and 50 ng/ml of the oligonucleotide probe. Sections were washed for 1 h in 2 Â SSC at room temperature and for 1 h in 0.2 Â SSC (10 Â SSC: 0.15 M Na citrate, 1.5 M NaCl, pH 7.0) at 421C, and then incubated with sheep antidigoxigenin antibody conjugated with calf intestinal alkaline phosphatase (Boehringer) for 3 h at room temperature, followed by development with nitro-blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl phosphate, toluidine salt (NBT/BCIP). Levamisol (0.15 mg/ml) was added to block residual endogenous alkaline phosphatase.
Western blot analysis
Muscle cryosections (50 mg/ml) were solubilized in sample buffer containing 18% SDS, 50 mM dithiothreitol, 5 mM EDTA, 0.1 M Tris-HCl pH 8.0, and 0.001% bromophenol blue. Total proteins were separated on 3-8% SDS-PAGE and blotted on nitrocellulose membranes. The blots were incubated with a monoclonal antibody against the N-terminus of utrophin (Novocastra, NCL-DRP2), followed by peroxidase-conjugated affinity purified goat anti-mouse IgG (Amersham International, Amersham Place, Buckinghamshire, UK). The signal was visualized by Enhanced Chemiluminescence (Amersham).
Histology and immunohistochemistry
Cryostat sections (6 mm-thick) were used for histology and immunohistochemistry. Sections were either stained with hematoxylin and eosin (HE), or Masson's trichrome, or incubated (90 min) with one of the following primary monoclonal antibodies: antiutrophin N-terminus NCL-DRP2 (dilution 1:5), anti-b-dystroglycan NCL-43 DAG (1:50), anti-b-sarcoglycan NCL-b SARC (1:50) (all from Novocastra, Newcastle-upon-Tyne, UK), anticollagen III (1:150) (Calbiochem, San Diego, CA, USA) and anticanine CD4 (1:50) (Serotec, Oxford, UK). To visualize utrophin, sections were subsequently incubated with Cy2-conjugated affinity-purified goat anti-mouse IgG (1:100) (Jackson ImmunoResearch, West Grove, PA, USA). To visualize CD4, b-dystroglycan and b-sarcoglyUtrophin gene transfer in CXMD M Cerletti et al can, sections were incubated with biotin-conjugated affinity-purified goat anti-mouse IgG (1:250) (Jackson ImmunoResearch) followed by rhodamine avidin D (1:500) (Vector Labs, Burlingame, CA, USA).
Sections were rinsed in PBS several times between each incubation. All steps were performed at room temperature in a humid chamber.
Quantitation and statistical analysis
At 30 and 60 days, the TA muscle had a maximum diameter of 10-12 and 18-20 mm, respectively, and was therefore divided into two or four parts of equal size prior to processing. We took at least 50 serial sections from each muscle block; we selected sections that contained areas positive for transgene, and counted all positive fibers in the section; then we determined the average percentage of such fibers relative to the total number of fibers in the section.
The total number of fibers per section was calculated as follows: 3-4 fields, for a total of 1500-2000 fibers, were randomly selected in the section and the total number of fibers per field was counted at Â 40 or Â 20 magnification for 30-and 60-day-old animals, respectively. The total number of fields contained in each section was calculated (39-48 fields per section) and multiplied by the average number of fibers per field.
In the 60-day-old cyclosporin-treated dystrophic animal, the extent of connective tissue was measured on collagen III immunostained sections adjacent to both highly transgene-positive and transgene-negative areas at magnification Â 20 using the NIH Image software version 1.62 (http://rsb.info.nih.gov/nih-image/). At least three fields from each area were analyzed in each section. Briefly, fields of equal size were photographed and digitalized; using Image software, a threshold was applied to the photographs to obtain black and white images with areas positive for collagen in black and areas negative in white. Manual corrections were sometimes applied to eliminate nonmuscle/nonfibrosis areas or to add areas not recognized by the software. The area positive for collagen III, as a percentage of the entire image, was calculated. We used the unpaired Student's ttest to assess the significance of differences in the extent of connective tissue.
Immunochemical detection
The presence of antibodies against mini-utrophin was assessed by immunohistochemistry as previously described. 32 Briefly, sections of muscles from an mdx mouse and from a Becker patient with clear evidence of utrophin upregulation were incubated with serum from immunosuppressed and nonimmunosuppressed dogs (5-, 30-and 60-day-old) at dilutions of 1:100 and 1:400, in negative control serum was from uninjected dystrophic dogs. Sections were then incubated with rabbit anti-dog IgG F(ab 0 ) 2 fragment conjugated to Cy3 (Jackson Immunoresearch, # 304-165-006).
Dog serum was also used (dilutions of 1:100 and 1:400) in an attempt to block the utrophin signal on mdx muscle sections. This was done by incubating sections with different dilutions of dog serum. The sections were then stained with utrophin antibody (goat antiutrophin N-19, Santa Cruz Biotechnology Inc., #SC-7460) followed by Cy3-conjugated F(ab') 2 fragment donkey anti-goat IgG (Jackson Immuno Research, #705-166-147).
The presence of antibodies against adenovirus was assessed using ELISA, as previously described. 32 The plates were coated with denatured first-generation adenovirus (100 ml of 1.0 Â 10 8 virus/ml per well). The sera were diluted 1:10 to 1:100 000 and applied to the wells; absorbance was measured after incubation of the wells with HRP-conjugated anti-dog IgG (1:1.000; SigmaAldrich, Inc., St Louis, MO, USA, #909). Negative controls (serum of uninjected dogs) were included on each plate. Titers were expressed as reciprocal of the sample dilution giving twice the absorbance of negative controls.
The cell-mediated immune response was determined in the 60-day-old animals by counting the number of mononucleated CD4-positive cells per 100 muscle fibers.
